Key result
Female sex was significantly associated with an increased risk of developing cisplatin-induced nephrotoxicity in diabetic patients with thoracic cancer (adjusted OR 2.87).
Why the study?
Baseline diabetes mellitus significantly worsens cisplatin-induced nephrotoxicity despite supportive care advances, prompting this study to identify further risk factors associated with nephrotoxicity development in diabetic patients.
What are the risk factors for cisplatin-induced nephrotoxicity in diabetic patients with thoracic cancer receiving short hydration?
Observational (n=140)
Yes
What are the risk factors for cisplatin-induced nephrotoxicity in diabetic patients with thoracic cancer receiving short hydration?
Odds Ratio: 2.87 (95% CI 1.08–7.67)
p-value: p=0.04
Female sex is a significant independent risk factor for cisplatin-induced nephrotoxicity in diabetic patients with thoracic cancer receiving short hydration.
The occurrence of cisplatin (CDDP)-induced nephrotoxicity (CIN) has decreased with advancements in supportive care. In contrast, we reported that baseline diabetes mellitus (DM) complications significantly worsen CIN. This study aimed to determine further risk factors associated with CIN development in DM patients. Patients with thoracic cancer requiring DM pharmacotherapy, who received CDDP (≥ 60 mg/m2)-containing regimens using the short hydration method (n = 140), were enrolled in this retrospective multicenter observational study. The primary endpoint of the present study was the elucidation of risk factors (patient factors, DM medication influence, and treatment-related factors) associated with CIN development in patients with DM. Cisplatin-induced nephrotoxicity occurred in 22.1% of patients with DM. The median worst variation of serum creatinine levels and creatinine clearance (worst level − baseline level) was 0.16 mg/dL (range: − 0.12–1.41 mg/dL) and − 15.9 mL/min (− 85.5–24.3 mL/min), respectively. Multivariate logistic regression analyses identified female sex as the singular risk factor for CIN development in the DM population (adjusted odds ratio; 2.87, 95% confidence interval; 1.08–7.67, P = 0.04). Diabetes mellitus medication and treatment-related factors did not affect CIN development. In conclusion, our study revealed that female sex is significantly associated with CIN development in patients with DM and thoracic cancer.
No takes yet. Share an insight, caveat, or question.
Saito et al. (2023) conducted an observational in Thoracic cancer with diabetes mellitus (n=140). Female sex vs. Male sex was evaluated on Development of cisplatin-induced nephrotoxicity (CIN) (adjusted OR 2.87, 95% CI 1.08-7.67, p=0.04). Female sex was significantly associated with an increased risk of developing cisplatin-induced nephrotoxicity in diabetic patients with thoracic cancer (adjusted OR 2.87).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: